NA
IOVA icon

Neuburgh Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Neuburgh Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$25K Sell
1,360
-238
-15% -$5.26K ﹤0.01% 874
2019
Q2 		$39K Hold
1,598
– – ﹤0.01% 870
2019
Q1 		$15K Sell
1,598
-170
-10% -$1.65K ﹤0.01% 894
2018
Q4 		$16K Buy
+1,768
New +$17.1K ﹤0.01% 868

Other funds holding IOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neuburgh Advisers's IOVA Position: Q3 2019 in Review

Neuburgh Advisers reduced its Iovance Biotherapeutics (IOVA) stake by 15% in Q3 2019, selling an estimated $5.26K and leaving 1,360 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #874.

Neuburgh Advisers first reported a position in IOVA in Q4 2018 and has held it in 4 quarters since. The position peaked at $39K in Q2 2019. 173 funds tracked by Wall St. Rank hold IOVA as of Q3 2019.

  • Neuburgh Advisers held 1,360 shares of Iovance Biotherapeutics worth $25K as of Q3 2019.
  • Neuburgh Advisers sold 238 Iovance Biotherapeutics shares in Q3 2019, an estimated $5.26K.
  • Iovance Biotherapeutics made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #874 holding.
  • Neuburgh Advisers first reported a position in Iovance Biotherapeutics in Q4 2018 and has held it in 4 quarters since.
  • Neuburgh Advisers's Iovance Biotherapeutics position peaked at $39K in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.